169 related articles for article (PubMed ID: 30407280)
1. Effect of Endostar combined with chemotherapy in advanced well-differentiated pancreatic neuroendocrine tumors.
Cheng YJ; Meng CT; Ying HY; Zhou JF; Yan XY; Gao X; Zhou N; Bai CM
Medicine (Baltimore); 2018 Nov; 97(45):e12750. PubMed ID: 30407280
[TBL] [Abstract][Full Text] [Related]
2. A retrospective study of capecitabine/temozolomide (CAPTEM) regimen in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs) after failing previous therapy.
Saif MW; Kaley K; Brennan M; Garcon MC; Rodriguez G; Rodriguez T
JOP; 2013 Sep; 14(5):498-501. PubMed ID: 24018594
[TBL] [Abstract][Full Text] [Related]
3. Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors.
Chan JA; Stuart K; Earle CC; Clark JW; Bhargava P; Miksad R; Blaszkowsky L; Enzinger PC; Meyerhardt JA; Zheng H; Fuchs CS; Kulke MH
J Clin Oncol; 2012 Aug; 30(24):2963-8. PubMed ID: 22778320
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors.
Kulke MH; Stuart K; Enzinger PC; Ryan DP; Clark JW; Muzikansky A; Vincitore M; Michelini A; Fuchs CS
J Clin Oncol; 2006 Jan; 24(3):401-6. PubMed ID: 16421420
[TBL] [Abstract][Full Text] [Related]
5. Capecitabine and temozolomide in grade 1/2 neuroendocrine tumors: a Spanish multicenter experience.
Crespo G; Jiménez-Fonseca P; Custodio A; López C; Carmona-Bayonas A; Alonso V; Navarro M; Aller J; Sevilla I; Grande E; Gajate P; Alonso-Gordoa T; Matos I; Capdevila J; Nieto B; Barriuso J
Future Oncol; 2017 Mar; 13(7):615-624. PubMed ID: 27802780
[TBL] [Abstract][Full Text] [Related]
6. Phase I-II study of radiopeptide 177Lu-octreotate in combination with capecitabine and temozolomide in advanced low-grade neuroendocrine tumors.
Claringbold PG; Price RA; Turner JH
Cancer Biother Radiopharm; 2012 Nov; 27(9):561-9. PubMed ID: 23078020
[TBL] [Abstract][Full Text] [Related]
7. Short article: Evaluation of O6-methylguanine-DNA methyltransferase as a predicting factor of response to temozolomide-based chemotherapy in well-differentiated metastatic pancreatic neuroendocrine tumors.
Girot P; Dumars C; Mosnier JF; Muzellec L; Senellart H; Foubert F; Caroli-Bosc FX; Cauchin E; Regenet N; Matysiak-Budnik T; Touchefeu Y
Eur J Gastroenterol Hepatol; 2017 Jul; 29(7):826-830. PubMed ID: 28328619
[TBL] [Abstract][Full Text] [Related]
8. A phase II multicenter randomized controlled trial to compare standard chemoradiation with or without recombinant human endostatin injection (Endostar) therapy for the treatment of locally advanced nasopharyngeal carcinoma: Long-term outcomes update.
Li Y; Tian Y; Jin F; Wu W; Long J; Ouyang J; Zhou Y
Curr Probl Cancer; 2020 Feb; 44(1):100492. PubMed ID: 32035692
[TBL] [Abstract][Full Text] [Related]
9. Fluorouracil, Doxorubicin with Streptozocin and Subsequent Therapies in Pancreatic Neuroendocrine Tumors.
Rogers JE; Lam M; Halperin DM; Dagohoy CG; Yao JC; Dasari A
Neuroendocrinology; 2022; 112(1):34-42. PubMed ID: 33434908
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the combination 5-fluorouracil, dacarbazine, and epirubicin in patients with advanced well-differentiated neuroendocrine tumors.
Walter T; Bruneton D; Cassier PA; Hervieu V; Pilleul F; Scoazec JY; Chayvialle JA; Lombard-Bohas C
Clin Colorectal Cancer; 2010 Oct; 9(4):248-54. PubMed ID: 20920998
[TBL] [Abstract][Full Text] [Related]
11. A prospective, phase 1/2 study of everolimus and temozolomide in patients with advanced pancreatic neuroendocrine tumor.
Chan JA; Blaszkowsky L; Stuart K; Zhu AX; Allen J; Wadlow R; Ryan DP; Meyerhardt J; Gonzalez M; Regan E; Zheng H; Kulke MH
Cancer; 2013 Sep; 119(17):3212-8. PubMed ID: 23733618
[TBL] [Abstract][Full Text] [Related]
12. The Evaluation of Durative Transfusion of Endostar Combined with Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer.
Li X; Gu G; Soliman F; Sanders AJ; Wang X; Liu C
Chemotherapy; 2018; 63(4):214-219. PubMed ID: 30347389
[TBL] [Abstract][Full Text] [Related]
13. Pancreatic Neuroendocrine Tumor Control: Durable Objective Response to Combination 177Lu-Octreotate-Capecitabine-Temozolomide Radiopeptide Chemotherapy.
Claringbold PG; Turner JH
Neuroendocrinology; 2016; 103(5):432-9. PubMed ID: 26065489
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant Capecitabine/Temozolomide for Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors.
Squires MH; Worth PJ; Konda B; Shah MH; Dillhoff ME; Abdel-Misih S; Norton JA; Visser BC; Dua M; Pawlik TM; Schmidt CR; Poultsides G; Cloyd JM
Pancreas; 2020 Mar; 49(3):355-360. PubMed ID: 32132509
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of FOLFOX in Patients with Aggressive Pancreatic Neuroendocrine Tumors After Prior Capecitabine/Temozolomide.
Al-Toubah T; Morse B; Pelle E; Strosberg J
Oncologist; 2021 Feb; 26(2):115-119. PubMed ID: 33225478
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of capecitabine and temozolomide combination in well-differentiated neuroendocrine tumors: Jordan experience.
Abbasi S; Kashashna A; Albaba H
Pancreas; 2014 Nov; 43(8):1303-5. PubMed ID: 25036906
[TBL] [Abstract][Full Text] [Related]
17. Ramucirumab in combination with dacarbazine in patients with progressive well-differentiated metastatic pancreatic neuroendocrine tumors (RamuNET): study protocol for a multicenter single-arm trial.
Krug S; Kegel T; Gress TM; Rinke A; Apostolidis L; Jann H; König A; Hörsch D; Schrader J; Ettrich TJ; Richter M; Steighardt J; Michl P
BMC Cancer; 2021 Nov; 21(1):1206. PubMed ID: 34772353
[TBL] [Abstract][Full Text] [Related]
18. Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience.
Fine RL; Gulati AP; Krantz BA; Moss RA; Schreibman S; Tsushima DA; Mowatt KB; Dinnen RD; Mao Y; Stevens PD; Schrope B; Allendorf J; Lee JA; Sherman WH; Chabot JA
Cancer Chemother Pharmacol; 2013 Mar; 71(3):663-70. PubMed ID: 23370660
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Temozolomide-Capecitabine to 5-Fluorouracile-Dacarbazine in 247 Patients with Advanced Digestive Neuroendocrine Tumors Using Propensity Score Analyses.
de Mestier L; Walter T; Brixi H; Evrard C; Legoux JL; de Boissieu P; Hentic O; Cros J; Hammel P; Tougeron D; Lombard-Bohas C; Rebours V; Ruszniewski P; Cadiot G
Neuroendocrinology; 2019; 108(4):343-353. PubMed ID: 30759445
[TBL] [Abstract][Full Text] [Related]
20. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas.
Strosberg JR; Fine RL; Choi J; Nasir A; Coppola D; Chen DT; Helm J; Kvols L
Cancer; 2011 Jan; 117(2):268-75. PubMed ID: 20824724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]